附属病院 総合周産期母子医療センター

矢田 ゆかり

Yukari Yada

基本情報

所属
自治医科大学 総合周産期母子医療センター 准教授

J-GLOBAL ID
200901073423420591
researchmap会員ID
1000209641

論文

 52
  • Miyuki Matano, Koyuru Kurane, Kei Wakabayashi, Yukari Yada, Yumi Kono, Toshihiro Tajima, Hitoshi Osaka, Yukifumi Monden
    Pediatrics international : official journal of the Japan Pediatric Society 66(1) e15742 2024年  
    BACKGROUND: Premature children are known to be at a high risk of developing behavioral problems. This study examined the effectiveness of parent-child interaction therapy (PCIT) in reducing behavioral problems in young children born premature. METHODS: The study included 18 child-parent pairs with children born at less than 35 weeks of gestation (range: 23-34 weeks, median: 31.0 weeks) and aged 27-52 months (median: 38.0 months). They were assigned to either the PCIT group (n = 7) or the non-PCIT group (n = 11) based on maternal desire for treatment. The study was designed to examine the effects of PCIT. Specifically, the Eyberg Child Behavior Inventory (ECBI) intensity score, ECBI problem score, and Parenting Stress Index Short Form (PSI-SF) scores were compared before treatment and after 6 months. RESULTS: In the PCIT group, the mean ECBI intensity score was 135.7 (SD = 13.5; T-score = 64) at baseline and 90.1 (SD = 15.5; T-score = 46) at post-assessment, the mean ECBI problem score was 9.8 (SD = 1.9; T-score = 54) at baseline and 4.4 (SD = 3.1; T-score = 44) at post-assessment, the mean PSI-SF total score was 60.1 (SD = 4.8; 95%tile) at baseline and 49.6 (SD = 5.6; 85%tile) at post-assessment, showing a significant improvement (ECBI intensity scores: p < 0.001, d = 2.03; ECBI problem scores: p < 0.001, d = 1.94; PSI-SF total scores: p = 0.004, d = 0.86). On the other hand, none of the scores showed significant change in the non-PCIT group. CONCLUSIONS: The PCIT can be considered as a potential treatment option for behavioral problems in young children born premature.
  • 若林 慶, 俣野 美雪, 小倉 一輝, 山上 彩香, 相楽 昌志, 小森 咲子, 下澤 弘憲, 鈴木 由芽, 西村 力, 矢田 ゆかり, 河野 由美
    日本新生児成育医学会雑誌 35(3) 521-521 2023年10月  
  • 俣野 美雪, 小倉 一輝, 山上 彩香, 小森 咲子, 相楽 昌志, 下澤 弘憲, 鈴木 由芽, 矢田 ゆかり, 河野 由美
    日本新生児成育医学会雑誌 34(3) 477-477 2022年10月  
  • Hironori Shimozawa, Tomoyuki Sato, Hitoshi Osaka, Atsuhito Takeda, Akihiko Miyauchi, Narumi Omika, Yukari Yada, Yumi Kono, Kei Murayama, Yasushi Okazaki, Yoshihito Kishita, Takanori Yamagata
    International heart journal 63(5) 970-977 2022年9月30日  
    Hypertrophic cardiomyopathy is a common cardiac complication in mitochondrial disorders, and the morbidity rate in neonatal cases is up to 40%. The mortality rate within 3 months for neonatal-onset mitochondrial cardiomyopathy is known to be high because there is currently no established treatment.We report the case of a male infant with neonatal-onset mitochondrial disorder presenting lactic acidosis and hypertrophic cardiomyopathy. Genetic analysis of the patient revealed recurrent m.13513G>A, p.Asp393Asn in mitochondrially encoded NADH dehydrogenase 5 gene (MT-ND5). Low-dose propranolol was initially administered for cardiomyopathy; however, he developed hypertrophic obstructive cardiomyopathy (HOCM) at 3 months of age. To reduce the risk of hypoglycemia associated with high-dose propranolol, cibenzoline, a class Ia antiarrhythmic drug, was added at a dose of 2.5 mg/kg/day and increased weekly to 7.5 mg/kg/day with monitoring of the blood concentration of cibenzoline. Left ventricular outflow tract stenosis (LVOTS) dramatically improved from 5.4 to 1.3 m/second in LVOTS peak velocity after 6 weeks, without notable adverse effects. The plasma N-terminal pro-brain natriuretic peptide level decreased from 65,854 to 10,044 pg/mL. Furthermore, myocardial hypertrophy also improved, as the left ventricular mass index decreased from 173.1 to 108.9 g/m2 after 3 months of the treatment.The administration of cibenzoline, in conjunction with low-dose propranolol, may serve an effective treatment for HOCM in infantile patients with mitochondrial disorders.
  • 矢田 ゆかり, 大口 昭英, 大槻 克文, 五石 圭司, 齋藤 滋, 楠田 聡
    日本周産期・新生児医学会雑誌 58(Suppl.1) 221-221 2022年6月  

MISC

 59

共同研究・競争的資金等の研究課題

 3